Populist administrative overhauls dismantle emergency-use frameworks in favor of alternative therapies and radical disclosure.
New regulatory leadership leverages proactive document releases and the wind-down of emergency declarations to divert focus from standard pharmaceutical paths toward alternative approvals.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The FDA's decision to resume publishing CRLs shows a commitment to radical administrative disclosure under new leadership.
Under new administrative priorities, the advisory committee overrode career scientists to recommend adding alternative therapies like peptides to bulk compounding lists.
HHS's termination of remaining COVID-19 EUAs represents a deliberate wind-down of emergency-era regulatory frameworks.